Financial Snapshot

Revenue
$812.0M
TTM
Gross Margin
29.09%
TTM
Net Earnings
-$212.6M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
247.28%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$3.483B
Q3 2024
Cash
Q3 2024
P/E
-5.438
Dec 02, 2024 EST
Free Cash Flow
-$82.21M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $788.9M $627.1M $628.4M $513.1M $405.3M $179.3M $43.13M $20.54M $12.64M
YoY Change 25.8% -0.2% 22.47% 26.59% 126.06% 315.73% 110.0% 62.43%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue $788.9M $627.1M $628.4M $513.1M $405.3M $179.3M $43.13M $20.54M $12.64M
Cost Of Revenue $565.6M $480.2M $511.6M $389.9M $309.3M $135.8M $28.86M $9.161M $9.974M
Gross Profit $223.4M $147.0M $116.8M $123.2M $96.05M $43.51M $14.28M $11.38M $2.670M
Gross Profit Margin 28.31% 23.43% 18.59% 24.01% 23.7% 24.27% 33.1% 55.39% 21.12%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Selling, General & Admin $204.6M $231.0M $197.7M $138.2M $148.5M $139.7M $64.41M $14.66M $8.500M
YoY Change -11.43% 16.82% 43.12% -6.94% 6.3% 116.84% 339.23% 72.51%
% of Gross Profit 91.6% 157.17% 169.26% 112.15% 154.56% 320.96% 451.17% 128.88% 318.35%
Research & Development $635.0K $682.0K $1.518M $830.0K $1.916M $1.052M $5.864M $3.171M $1.136M
YoY Change -6.89% -55.07% 82.89% -56.68% 82.13% -82.06% 84.93% 179.14%
% of Gross Profit 0.28% 0.46% 1.3% 0.67% 1.99% 2.42% 41.08% 27.87% 42.55%
Depreciation & Amortization $126.9M $130.1M $154.6M $67.83M $35.67M $17.21M $3.562M $1.853M $1.953M
YoY Change -2.49% -15.81% 127.9% 90.17% 107.26% 383.16% 92.23% -5.12%
% of Gross Profit 56.82% 88.56% 132.34% 55.07% 37.13% 39.55% 24.95% 16.29% 73.15%
Operating Expenses $398.1M $326.0M $727.2M $255.4M $200.1M $182.4M $70.27M $17.83M $1.136M
YoY Change 22.11% -55.17% 184.79% 27.64% 9.66% 159.63% 294.02% 1469.89%
Operating Profit -$174.7M -$179.1M -$610.4M -$132.2M -$104.0M -$138.9M -$57.65M -$7.498M -$7.049M
YoY Change -2.4% -70.67% 361.83% 27.08% -25.14% 140.99% 668.87% 6.37%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Interest Expense $49.26M -$318.9M $39.68M $30.90M $25.64M $5.259M -$9.110M -$1.686M -$1.019M
YoY Change -115.45% -903.57% 28.4% 20.51% 387.62% -157.73% 440.33% 65.46%
% of Operating Profit
Other Income/Expense, Net -$37.84M -$7.971M $197.7M -$184.8M $14.20M $95.53M $2.010M $12.00K -$1.000K
YoY Change 374.75% -104.03% -206.94% -1402.13% -85.14% 4652.94% 16650.0% -1300.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Pretax Income -$249.0M -$1.450B -$440.7M -$345.0M -$109.2M -$38.14M -$72.17M -$7.809M -$7.883M
YoY Change -82.83% 229.08% 27.74% 215.96% 186.29% -47.16% 824.24% -0.94%
Income Tax -$26.62M -$7.181M -$6.542M -$8.972M -$8.352M -$2.045M -$4.451M $0.00 $0.00
% Of Pretax Income
Net Earnings -$245.0M -$1.453B -$476.8M -$367.4M -$102.5M -$25.04M -$67.72M -$7.809M -$7.883M
YoY Change -83.14% 204.67% 29.77% 258.32% 309.55% -63.03% 767.24% -0.94%
Net Earnings / Revenue -31.05% -231.64% -75.88% -71.61% -25.3% -13.96% -157.02% -38.02% -62.35%
Basic Earnings Per Share -$0.33 -$2.35 -$0.90 -$1.25 -$0.47 -$0.18
Diluted Earnings Per Share -$0.33 -$2.35 -$0.90 -$1.25 -$0.47 -$0.18 -$815.7K -$84.97K -$86.06K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Cash & Short-Term Investments $260.5M $448.5M $415.9M $488.5M $189.7M $96.80M $517.6M $2.300M $7.500M
YoY Change -41.92% 7.84% -14.85% 157.49% 95.97% -81.3% 22404.35% -69.33%
Cash & Equivalents $228.3M $206.6M $415.9M $488.5M $189.7M $96.80M $487.3M
Short-Term Investments $32.18M $241.9M $0.00 $30.30M
Other Short-Term Assets $63.41M $37.72M $46.79M $39.59M $22.50M $31.30M $3.000M $500.0K $100.0K
YoY Change 68.09% -19.37% 18.18% 75.95% -28.12% 943.33% 500.0% 400.0%
Inventory $252.1M $200.6M $245.5M $256.4M $93.60M $87.90M $16.20M $7.400M $4.100M
Prepaid Expenses
Receivables $101.7M $86.23M $95.28M $87.31M $29.00M $36.90M $16.50M $1.000M $400.0K
Other Receivables $0.00 $0.00 $0.00 $11.82M $12.20M $6.100M $1.000M $1.100M $0.00
Total Short-Term Assets $677.7M $773.0M $803.5M $883.6M $347.0M $259.0M $554.3M $12.40M $12.10M
YoY Change -12.33% -3.79% -9.07% 154.64% 33.98% -53.27% 4370.16% 2.48%
Property, Plant & Equipment $574.3M $435.6M $600.5M $669.0M $217.5M $201.7M $80.20M $40.00M $19.90M
YoY Change 31.85% -27.46% -10.24% 207.57% 7.83% 151.5% 100.5% 101.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $7.859M $12.37M $15.00M $25.79M $23.70M $35.60M $16.90M
YoY Change -36.47% -17.54% -41.83% 8.82% -33.43% 110.65%
Other Assets $5.395M $222.0K $314.0K $8.285M $4.400M $7.900M $800.0K $600.0K $200.0K
YoY Change 2330.18% -29.3% -96.21% 88.3% -44.3% 887.5% 33.33% 200.0%
Total Long-Term Assets $3.544B $3.534B $4.646B $5.142B $598.9M $637.3M $102.4M $41.50M $21.00M
YoY Change 0.28% -23.93% -9.64% 758.53% -6.03% 522.36% 146.75% 97.62%
Total Assets $4.222B $4.307B $5.450B $6.025B $945.9M $896.3M $656.7M $53.90M $33.10M
YoY Change
Accounts Payable $105.4M $70.82M $68.60M $57.71M $17.80M $39.10M $10.60M $5.600M $800.0K
YoY Change 48.82% 3.23% 18.89% 224.19% -54.48% 268.87% 89.29% 600.0%
Accrued Expenses $131.2M $107.4M $89.38M $144.0M $41.40M $51.40M $14.80M $2.000M $1.100M
YoY Change 22.19% 20.11% -37.91% 247.72% -19.46% 247.3% 640.0% 81.82%
Deferred Revenue
YoY Change
Short-Term Debt $18.03M $23.38M $18.12M $8.717M $0.00 $0.00 $0.00 $32.80M $20.10M
YoY Change -22.87% 29.01% 107.9% -100.0% 63.18%
Long-Term Debt Due $16.93M $198.5M $67.82M $37.27M $1.500M $500.0K $9.800M $0.00
YoY Change -91.47% 192.61% 81.96% 2384.87% -94.9%
Total Short-Term Liabilities $299.2M $433.0M $280.3M $401.2M $181.3M $92.40M $25.90M $50.20M $22.00M
YoY Change -30.9% 54.45% -30.13% 121.31% 96.21% 256.76% -48.41% 128.18%
Long-Term Debt $331.9M $368.8M $519.8M $870.6M $306.3M $444.4M $428.7M $8.600M $8.600M
YoY Change -10.02% -29.05% -40.29% 184.23% -31.08% 3.66% 4884.88% 0.0%
Other Long-Term Liabilities $16.56M $8.151M $11.52M $22.37M $35.20M $20.90M
YoY Change 103.21% -29.24% -48.51% -36.44% 68.42%
Total Long-Term Liabilities $348.4M $377.0M $531.3M $893.0M $341.5M $465.3M $428.7M $8.600M $8.600M
YoY Change -7.57% -29.05% -40.5% 161.48% -26.61% 8.54% 4884.88% 0.0%
Total Liabilities $778.8M $991.6M $1.051B $1.566B $572.1M $611.1M $459.0M $58.80M $30.60M
YoY Change -21.46% -5.64% -32.91% 173.78% -6.38% 33.14% 680.61% 92.16%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016
Basic Shares Outstanding 742.6M 618.0M 481.2M 269.5M 216.2M 203.5M
Diluted Shares Outstanding 742.6M 618.0M 481.2M 269.5M 216.2M 203.5M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $1.1562 Billion

About Tilray Brands, Inc.

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. The company is headquartered in New York City, New York and currently employs 2,650 full-time employees. The company went IPO on 2018-07-19. The firm operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The firm offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.

Industry: Medicinal Chemicals & Botanical Products Peers: Amphastar Pharmaceuticals, Inc. Amylyx Pharmaceuticals, Inc. CASSAVA SCIENCES INC CinCor Pharma, Inc. JOHNSON & JOHNSON Revance Therapeutics, Inc. SUPERNUS PHARMACEUTICALS, INC. Ventyx Biosciences, Inc.